Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LGLigand Pharmaceuticals, Inc. logo

Ligand Pharmaceuticals, Inc. (LGNZZ)

Other OTC · Currency in USD
$0.07 ▲ +0.01 (+7.69%)
At close: Oct 20, 3:29 PM ET. Market closed.

Summary

Previous Close
$0.07
Open
$0.07
Day's Range
$0.07 – $0.07
52 Week Range
$0.06 – $0.17
Volume
500
Avg. Volume
50,000
Market Cap
$1.40M
Beta (5Y Monthly)
0.98
PE Ratio (TTM)
0.01
EPS (TTM)
$9.83
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Ligand Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full-time employees
47
CEO
Todd C. Davis
Website
ligand.com

Ligand Pharmaceuticals, Inc. operates as a global biopharmaceutical firm dedicated to advancing and licensing pharmaceutical assets. The company's portfolio features a diverse array of therapies addressing critical health conditions. Key products include Kyprolis and Evomela, both indicated for multiple myeloma; Rylaze, an effective treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in pediatric and adult populations; and Filspari, a dual antagonist in development for rare kidney diseases and immunoglobulin A nephropathy.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $2.33 · Revenue est. $77.00M
DateEst.Actual
Aug 6, 2026$2.01$2.37Beat
May 7, 2026$1.82$1.63Miss
Feb 26, 2026$1.50$2.02Beat
Nov 6, 2025$1.93$3.09Beat
Aug 8, 2025$1.42$1.60Beat
May 8, 2025$1.21$1.33Beat

Analyst view

Rating: Buy
Buy 58% · Hold 33% · Sell 8%

Get free alerts on LGNZZ and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.